Cerus Corporation
CERS
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Sysā¦ read more
Healthcare
Medical Devices
29 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.15
Price-25.61%
-$0.74
1Y
Price
Market Cap
$430.793m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+4.9%
EBITDA Margin+0.0%
Net Profit Margin+0.2%
Free Cash Flow Margin+4.9%
EBITDA Margin+0.0%
Net Profit Margin+0.2%
Free Cash Flow MarginRevenue
$221.551m
+10.5%
1y CAGR+7.4%
3y CAGR+11.5%
5y CAGREarnings
-$6.783m
+23.7%
1y CAGR+26.8%
3y CAGR+25.4%
5y CAGREPS
-$0.03
+27.3%
1y CAGR+29.1%
3y CAGR+28.1%
5y CAGRBook Value
$70.715m
$205.187m
Assets$134.472m
Liabilities$76.799m
DebtDebt to Assets
37.4%
-16.7x
Debt to EBITDAFree Cash Flow
-$1.829m
-98.0%
1y CAGR-17.7%
3y CAGR-8.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company